FDA Approves One-Minute HIV Self-Test in Major Public Health Advancement
The FDA's approval of bioLytical's INSTI® HIV Self Test, which provides results in 60 seconds, represents a significant step toward reducing undiagnosed HIV cases and supporting national goals to end the HIV epidemic by making testing more accessible and private.
The U.S. Food and Drug Administration has approved the INSTI® HIV Self Test from bioLytical Laboratories Inc., marking the first one-minute HIV self-test available to American consumers. This approval represents a significant advancement in HIV prevention efforts, particularly given that approximately 13% of the estimated 1.2 million Americans living with HIV remain undiagnosed, and most new infections come from individuals unaware of their status.
The test's 60-second results timeframe addresses critical barriers to traditional healthcare access, including stigma, cost, and geographical limitations. Robert Mackie, CEO of bioLytical, emphasized that "HIV testing should be simple, fast, and accessible for everyone. By offering accurate results in just 60 seconds, we are empowering people to take control of their health, without waiting for clinic appointments or lab results." The portable, discreet design allows testing anywhere, providing immediate answers that can reduce transmission risk and improve treatment outcomes.
This development supports the U.S. public health initiative Ending the HIV Epidemic, which aims to reduce new HIV infections by 90% by 2030. With over 30,000 new infections occurring annually in the U.S., expanding testing access through self-administered options is crucial. Ana Subramanian, Vice President of Scientific Affairs at bioLytical, noted that "The FDA approval of the INSTI® HIV Self Test reflects both the scientific integrity of our work and our commitment to expanding access to rapid, reliable diagnostics."
The test requires only a single drop of blood from a fingertip and offers high accuracy alongside convenience. Its shelf-stable, portable nature makes it ideal for on-the-go testing, providing privacy without the need for appointments. The INSTI® HIV Self Test will soon be available at major retailers and online, with updates accessible through bioLytical's website.
By manufacturing the test in its ISO 13485:2016-certified facility, bioLytical ensures quality standards are met. This approval not only addresses immediate testing needs but also aligns with broader public health statistics and goals outlined by resources like HIV.gov. As Mackie stated, "This test is a powerful tool in the fight against HIV, providing immediate answers when they matter most," highlighting its potential to reduce undiagnosed cases and connect individuals to care sooner.